Refine
Year of publication
- 2009 (158) (remove)
Document Type
- Article (81)
- Doctoral Thesis (69)
- Book (5)
- Report (3)
Has Fulltext
- yes (158)
Is part of the Bibliography
- no (158)
Keywords
- Gentherapie (3)
- ADC (2)
- Biochemie (2)
- Crystallography (2)
- HIV (2)
- Kraftmikroskopie (2)
- Licht-Sammel-Komplex (2)
- Ligand <Biochemie> (2)
- Membranproteine (2)
- Quantenchemie (2)
Institute
- Biochemie und Chemie (158) (remove)
Die 5-Lipoxygenase (5-LO) ist das Schlüsselenzym in der Biosynthese proinflammatorischer Leukotriene, die maßgeblich an der Entstehung allergischer und entzündlicher Erkrankungen wie Arthritis, Asthma und kardiovaskulären Erkrankungen beteiligt sind (23). Humane 5-LO besteht aus 673 Aminosäuren und besitzt ein Molekulargewicht von 77,8 kDa (25). Das Protein besteht aus einer größeren katalytischen Domäne, die ein zentrales Eisen(II)-Atom enthält, dass für die zweistufige LTA4-Bildung aus Arachidonsäure benötigt wird, und einer kleineren C2-ähnlichen Domäne, die Bereiche für die Membran- sowie Ca2+-Bindung enthält. Durch Stimulation von intakten Zellen kommt es zu einer Translokation der 5-LO an die Kernmembran. Die Wechselwirkung mit dem membranständigen FLAP fördert die 5-LO-Leukotrienbildung. Die vorliegende Arbeit beschäftigte sich mit niedermolekularen Modifikationen der 5-LO durch U-73122 und Glutathion sowie mit der Charakterisierung von 5-LO-Inhibitoren. U-73122 ist ein Inhibitor, der in vitro und in vivo mit einem IC50-Wert von 30 nM bzw. 2,4 µM die 5-LO-Aktivität hemmt (2). U-73122 verfügt über eine thiol-reaktive Maleinimid-Gruppe, wodurch die Substanz kovalent an einige 5-LO-Cysteine (Cys-99, -159 und weitere) binden kann. Entsprechende U-73122-5-LO-Peptide konnten nach Trypsin-Verdau der 5-LO mit MALDI-MS-Messungen nachgewiesen werden. Für diesen Zweck musste eine effiziente Aufreinigung für native 5-LO (Reinheit > 95%) entwickelt werden. Um die Veränderung der 5-LO-Aktivität nach U-73122-Zugabe zu untersuchen, wurden Cystein/Serin-5-LO-Mutanten hergestellt. Es konnte festgestellt werden, dass die Mutante C416S-5-LO nicht mehr effektiv durch U-73122 gehemmt werden konnte. Daher ist anzunehmen, dass U-73122 an Cystein-416 der 5-LO bindet und die 5-LO-Produktbildung hemmt. Auf der 5-LO-Oberfläche kann ein Bereich lokalisiert werden, der einen Zugang für das Substrat zum aktiven Zentrum der 5-LO bilden könnte (238,239). Dieser Bereich liegt in unmittelbarer Nähe zu Cystein-416. Daher besteht die Möglichkeit, dass U-73122, nachdem es an Cystein-416 gebunden hat, diesen Bereich hemmend beeinflussen kann. Es konnte nachgewiesen werden, dass Glutathion an mehrere Cysteine der 5-LO (Cystein-99, -264 und -449) kovalent binden kann. Um Veränderungen der 5-LO-Aktivität durch in vivo Glutathionylierungen zu zeigen, wurden HeLa-Zellen mit 5-LO, Cystein-/Serin-5-LO-Mutanten sowie FLAP transfiziert und mit Diamid inkubiert. Es konnte festgestellt werden, dass die native sowie FLAP-gesteigerte 5-LO-Produktbildung durch Diamid gehemmt wird. Dies konnte ebenfalls für die Mutante 3W-5-LO beobachtet werden. Zusätzlich wurden verschiedene Cystein-/Serin-5-LO-Punktmutanten sowie eine 4fach Mutante (C159S/C300S/C416S/C418S-5-LO = 2D-5-LO) untersucht. Das Verhalten dieser Mutanten konnte in drei Gruppen eingeteilt werden. Gruppe A (C159S-, C300S- und C418S-5-LO) wurde durch Diamid nicht beeinflusst. Gruppe B (C416S- und 2D-5-LO) zeigte eine sehr starke Stimulation der 5-LO±FLAP-Leukotrienbildung nach Zugabe von Diamid. Bei Gruppe C (C99S-, C264S- und C449S-5-LO) konnte eine FLAP-gesteigerte 5-HETE-Bildung beobachtet werden. Durch Diamid kommt es zu Glutathionylierungen von zellulären Proteinen, da reduziertes Glutathion (GSH) zu reaktiveren oxidierten Glutathion (GSSG) umgesetzt wird. An der 5-LO-Oberfläche können in Folge an verschiedenen Cysteinen Glutathione binden. Durch die Glutathion-Bindung wird eine stark polare Struktur auf der 5-LO-Oberfläche eingebracht. Dadurch kommt es zu einer verminderten Membranbindung und Produktbildung der nativen 5-LO. Die 5-LO-Oberfläche der 2D-5-LO-Mutante kann an verschiedenen Positionen keine Glutathione mehr binden, es kommt es zu einer stärkeren Wechselwirkung mit Membranbestandteilen und zu einer erhöhten 5-LO-Leukotrienbildung. Für Celecoxib konnte gezeigt werden, dass neben der COX2-Hemmung auch die 5-LO-Aktivität mit einem IC50-Wert von 3-10 µM gehemmt werden kann (268). Im Rahmen dieser Arbeit wurden HeLa-Zellen mit 5-LO±FLAP transfiziert, um den Einfluss von Celecoxib auf FLAP zu untersuchen. Celecoxib führt zu einer direkten Hemmung der 5-LO. ML3000 (Licofelon) wurde als dualer COX/5-LO-Inhibitor entwickelt und hemmt die 5-LO-Aktivität in intakten Zellen, aber nicht im Homogenat. Daher wurden Versuche mit 5-LO±FLAP-tranfizierten HeLa-Zellen durchgeführt, um den Einfluss von ML3000 auf die FLAP-gesteigerte 5-LO-Leukotrienbildung zu zeigen. Aus diesen und weiteren Ergebnissen unserer Arbeitsgruppe konnte gefolgert werden, dass ML3000 ein FLAP-Inhibitor ist (277). Garsubellin A ist strukturverwandt zu Hyperforin, einem dualen COX/5-LO-Inhibitor (204). Garsubellin A hemmt die 5-LO-Aktivität im Homogenat von PMNL und am gereinigten Enzym mit einer IC50 von 10-30 µM. Verbindungen, die den Bicyclo[3.3.1]nonan-Grundkörper des Garsubellin A und Hyperforin enthalten, wurden auf ihr inhibitorisches Potential getestet. Es konnte gezeigt werden, dass der Bicyclo[3.3.1]nonan-Grundkörper alleine nicht für eine 5-LO-Hemmung ausreicht, sondern eine freie Carbonsäure sowie eine bis zwei Prenylierungen vorliegen müssen, um eine 5-LO-Hemmung zu erzielen. Sind diese Voraussetzungen vorhanden, wird die 5-LO-Aktivität in intakten PMNL mit einer IC50 von 10 µM und an gereinigter 5-LO mit 0,3-1 µM gehemmt.
Background: Nitric oxide (NO) is an essential vasodilator. In vascular diseases, oxidative stress attenuates NO signaling by both chemical scavenging of free NO and oxidation and down-regulation of its major intracellular receptor, the alpha/beta heterodimeric heme-containing soluble guanylate cyclase (sGC). Oxidation can also induce loss of sGC's heme and responsiveness to NO.
Results: sGC activators such as BAY 58-2667 bind to oxidized/heme-free sGC and reactivate the enzyme to exert disease-specific vasodilation. Here we show that oxidation-induced down-regulation of sGC protein extends to isolated blood vessels. Mechanistically, degradation was triggered through sGC ubiquitination and proteasomal degradation. The heme-binding site ligand, BAY 58-2667, prevented sGC ubiquitination and stabilized both alpha and beta subunits.
Conclusion: Collectively, our data establish oxidation-ubiquitination of sGC as a modulator of NO/cGMP signaling and point to a new mechanism of action for sGC activating vasodilators by stabilizing their receptor, oxidized/heme-free sGC.
A generic drug product (World Health Organization (WHO) terminology: multisource product) is usually marketed and manufactured after the expiry date of the innovator’s patent. Generic drugs are less expensive than the innovator products because generic manufacturers do not have to amortize the investment costs of research, development, marketing, and promotion. Multisource products must contain the same active pharmaceutical ingredients (APIs) as the original formulation and have to be shown to be interchangeable with the original formulation. Multisource products have to be shown bioequivalent to the innovator counterpart with respect to pharmacokinetic and pharmacodynamic properties. Multisource products are therefore identical in dose, strength, route of administration, safety, efficacy, and intended use. Bioequivalence can be demonstrated by in vitro dissolution, pharmacokinetic, pharmacodynamic or clinical studies. Since 2000, the U.S. Food and Drug Administration (FDA) allows the approval of certain multisource products solely on the basis of in vitro studies, i.e. by waiving in vivo studies in humans (“Biowaiver”), based on the Biopharmaceutics Classification Scheme (BCS). The BCS characterizes APIs by their solubility and permeability in the gastrointestinal tract (GIT). The different BCS Classes I-IV (Class I: high solubility, high permeability; Class II: low solubility, high permeability; Class III: high solubility, low permeability and Class IV: low solubility, low permeability) result from all possible combinations of high and low solubility with high and low permeability. Since the adoption of the BCS by the FDA in 1995, the BCS criteria have been under continuous development. In 2006, the WHO has released the most recent bioequivalence guidance including relaxed criteria for bioequivalence studies based on modified BCS criteria. According to this guidance, APIs belonging to the BCS classes I – and under defined conditions - II and III – are eligible for a biowaiver-based approval. The principal objective of this work was to characterize the first-line anti tuberculosis APIs, isoniazid, pyrazinamide, ethambutol dihydrochloride and rifampicin, according to their physicochemical, biopharmaceutical, pharmacokinetic and pharmacological properties and to classify them according to the BCS. Ethambutol dihydrochloride and isoniazid were classified as borderline BCS class I/III APIs. Pyrazinamide was classified as a BCS class III and rifampicin as a BCS class II API. Based on the BCS classification and the additional criteria defined in the WHO bioequivalence guidance, the possibility of biowaiver-based approval for immediate release (immediate release) solid oral dosage forms containing the first-line antituberculosis drugs was evaluated. A biowaiver-based approval with defined constraints was recommended for immediate release solid oral dosage forms containing isoniazid (interaction with reducing sugars), pyrazinamide and ethambutol dihydrochloride (relative narrow therapeutic index). Rifampicin was classified as a BCS class II API, and it was concluded that rifampicin containing solid oral immediate release drug products as well as Scale-Up and Post-Approval Changes (SUPAC) changes should not be approved by a biowaiver on the following basis: (i) its solubility and dissolution are highly variable due to polymorphism and instability, (ii) concomitant intake of food and antacids reduces its absorption and bioavailability, (iii) no in vitro predictive dissolution test has been found which correlates to in vivo absorption and (iv) several publications reporting cases of non-bioequivalent and bioinequivalent rifampicin products have been located in the literature. Thus, it is recommended that bioequivalence of rifampicin containing solid oral immediate release drug products should be established by in vivo pharmacokinetic studies in humans. This risk-benefit benefit assessment of a biowaiver-based approval was presented as a poster at the American Association of Pharmaceutical Scientists (AAPS) 2005 and subsequently published as “Biowaiver Monographs” in the Journal of Pharmaceutical Sciences. Based on the assessment of the dissolution properties of the antituberculosis drugs for a biowaiver approval, quality control dissolution methodologies for the International Pharmacopoeia (Pharm. Int.) were developed, presented at the WHO expert meeting and adopted in the Pharm. Int. (http://www.who.int/medicines/publications/pharmprep/OMS_TRS_948.pdf). Additionally, preliminary biowaiver recommendations were also developed for four firstline antimalarial drugs listed on the WHO Essential Medicines List (EML): Quinine, as both the hydrochloride and sulphate, and proguanil hydrochloride were classified as borderline BCS class I/III APIs. Since quinine is a narrow therapeutic index drug and many cases of non-bioequivalence have been reported in the literature, a biowaiverbased approval was not recommended. For solid oral immediate release dosage forms containing proguanil a biowaiver-based approval was recommended under the condition that they dissolve very rapidly. Primaquine phosphate was classified as a BCS class I API. Therefore, a biowaiver-based approval was recommended for immediate release solid oral dosage forms containing primaquine phosphate. Mefloquine hydrochloride was classified as a basic, BCS class IV/II API, making it ineligible for the biowaiver. Additionally, reports of non-bioequivalence and a narrow therapeutic index were found in the scientific literature. Consequently, bioequivalence of solid oral immediate release dosage forms containing mefloquine hydrochloride should be established by in vivo pharmacokinetic studies. The results for quinine hydrochloride and sulphate, proguanil hydrochloride, primaquine diphosphate and mefloquine hydrochloride were presented as a poster at the Pharmaceutical Sciences World Congress (PSWC) 2007 and published as a WHO Collaborating Center Report in June 2006. The aim of this project was to collect, evaluate, generate and publish relevant information for a biowaiver-based approval of essential medicines in order to provide a summary to local regulatory authorities. This information complements the selected list of essential medicines by providing information about the biopharmaceutical properties and pharmaceutical quality of solid oral immediate release dosage forms containing these APIs. The aim of the biowaiver project, inspired by the WHO and brought in life by the International Pharmaceutical Federation (FIP), is to enable access to essential medicines in standardized quality at an affordable price. In this work, a significant contribution to this aim in the form of four biowaiver monographs for the antituberculosis drugs and several reports on the antimalarials has been achieved.
Background: Microarray analysis still remains a powerful tool to identify new components of the transcriptosome and it has helped to increase the knowledge of targets triggered by stress conditions such as hypoxia and nitric oxide. However, analysis of transcriptional regulatory events remain elusive due to the contribution of altered mRNA stability to gene expression patterns, as well as changes in the half-life of mRNAs, which influence mRNA expression levels and their turn over rates. To circumvent these problems, we have focused on the analysis of newly transcribed (nascent) mRNAs by nuclear run on (NRO), followed by microarray analysis. Result: We identified 188 genes that were significantly regulated by hypoxia, 81 genes were affected by nitric oxide, and 292 genes were induced by the co-treatment of macrophages with both NO and hypoxia. Fourteen genes (Bnip3, Ddit4, Vegfa, Trib3, Atf3, Cdkn1a, Scd1, D4Ertd765e, Sesn2, Son, Nnt, Lst1, Hps6 and Fxyd5) were common to hypoxia and/or nitric oxide treatments, but with different levels of expression. We observed that 166 transcripts were regulated only when cells were co-treated with hypoxia and NO but not with either treatment alone, pointing to the importance of a crosstalk between hypoxia and NO. In addition, both array and proteomics data supported a consistent repression of hypoxia regulated targets by NO. Conclusion: By eliminating the interference of steady state mRNA in gene expression profiling, we increased the sensitivity of mRNA analysis and identified previously unknown hypoxia-induced targets. Gene analysis profiling corroborated the interplay between NO- and hypoxia-induced signalling.
Photo-initiated processes, like photo-excitation and -deexcitation, internal conversion, excitation energy transfer and electron transfer, are of importance in many areas of physics, chemistry and biology. For the understanding of such processes, detailed knowledge of excitation energies, potential energy surfaces and excited state properties of the involved molecules is an essential prerequisite. To obtain these informations, quantum chemical calculations are required. Several quantum chemical methods exist which allow for the calculation of excited states. Most of these methods are computationally costly what makes them only applicable to small molecules. However, many biological systems where photo-processes are of interest like light-harvesting complexes in photosynthesis or the reception of light in the human eye by rhodopsin are quite large. For large systems, however, only few theoretical methods remain applicable. The currently most widely used method is time-dependent density functional theory (TD-DFT), which can treat systems of up to 200–300 atoms with the excitation energies of some excited states exhibiting errors of less than 0.5 eV. Yet, TD-DFT has several drawbacks. The most severe failure of TD-DFT is the false description of charge transfer states which is particularly problematic in case of larger systems where it yields a multitude of artificially low-lying charge transfer states. But also Rydberg states and states with large double excitation character are not described correctly. Still, if these deficiencies are kept in mind during the interpretation of results, TD-DFT is a useful tool for the calculation of excited states. In my thesis, TD-DFT is applied in investigations of excitation energy and electron transfer processes in light-harvesting complexes. Since light-harvesting complexes, which consist of thousands of atoms, are by far too large to be calculated, model complexes for the processes of interest are constructed from available crystal structures. The model complexes are used to calculate potential energy curves along meaningful reaction coordinates. Artificial charge transfer states are corrected with the help of the so-called ∆DFT method. The resulting potential energy curves are then interpreted by comparison with experimental results. For the light-harvesting complex LH2 from purple bacteria the experimentally observed formation of carotenoid radical cations is studied. It is shown that the carotenoid radical cation is formed most likely via the optically forbidden S1 state of the carotenoid. In light-harvesting complex LHC-II of green plants the fast component of the so-called non-photochemical quenching (NPQ) is investigated. Two of several different hypotheses on the mechanism of NPQ, which have been proposed recently, are studied in detail. The first one suggests that NPQ proceeds via simple replacement of violaxanthin by zeaxanthin in the binding pocket in LHC-II. However, the calculated potential energy curves exhibit no difference between violaxanthin and zeaxanthin in the binding pocket. In combination with experimental results it is thus shown that simple replacement alone does not mediate NPQ in LHC-II. The second hypothesis proposes conformational changes of LHC-II that lead to quenching at the central lutein and chlorophyll molecules during NPQ. My TD-DFT calculations demonstrate that if this mechanism is operative, only the lutein 1 which is one of two central luteins present in LHC-II can take part in the quenching process. This is corroborated by recent experiments. Though several conclusions can be drawn from the investigations using TD-DFT, the interpretability of the results is limited due to the deficiencies of the method and of the models. To overcome the methodological deficiencies, more accurate methods have to be employed. Therefore, the so-called algebraic diagrammatic construction scheme (ADC) is implemented. ADC is a widely overlooked ab initio method for the calculation of excited states, which is based on propagator theory. Its theoretical derivation proceeds via perturbation expansion of the polarization propagator, which describes electronic excitations. This yields separate schemes for every order of perturbation theory. The second order scheme ADC(2), which is employed here, is the equivalent to the Møller-Plesset ground state method MP(2), but for excited states. It represents the computationally cheapest excited state method which can correctly describe doubly excited states, as well as Rydberg and charge transfer states. The quality of ADC(2) results is demonstrated in calculations on linear polyenes which serve as model systems for the larger carotenoid molecules. The calculations show that ADC(2) describes the three lowest excited states of polyenes sufficiently well, particularly the optically forbidden S1 state which is known to possess large double excitation character. Yet, the applicability of the method is limited compared to TD-DFT due to the much larger computational requirements. To facilitate the calculation of larger systems with ADC(2) a new variant of the method is developed and implemented. The variant employs the short-range behavior of electron correlation to reduce the computational effort. As a first step, the working equations of ADC(2) are transformed into a basis of local orbitals. In this basis negligible contributions of the equations which are due to electron correlation can be identified based on the distances of local orbitals. A so-called “bumping” scheme is implemented which removes the negligible parts during a calculation. This way, the computation times as well as the disk space requirements can be reduced. With the “bumping” scheme several new parameters are introduced that regulate the amount of “bumping” and thereby the speed and the accuracy of computations. To determine useful values for the parameters an evaluation is performed using the linear polyene octatetraene as test molecule. From the evaluation an optimal set of parameter values is obtained, so that the computation times become minimal, while the errors in the excitation energies due to the “bumping” do not exceed 0.15 eV. With further calculations on various molecules of different sizes it is tested if these parameter values are universal, i.e. if they can be used for all molecules. The test calculations show that the errors in the excitation energies are below 0.15 eV for all test systems. Additionally, no trend is visible for the errors that their magnitude might depend on the system. In contrast, the amount of disregarded contributions in the calculations increases drastically with growing system size. Thus, the local variant of ADC(2) can be used in future to reliably calculate excited states of systems which are not accessible with conventional ADC(2).
In der vorliegenden Arbeit konnte gezeigt werden, dass bei verschiedenen Hämostasedefekten eine unterschiedliche Aktivierung des Gerinnungssystems besteht. So wiesen Personen mit heterozygoter Prothrombin-Mutation (G20210A) eine massiv erhöhte Thrombinbildung auf, während sie in den üblichen Globaltests (Prothrombinzeit (PT) und aktivierte partielle Thromboplastinzeit (aPTT)) und der Thrombinzeit (TZ) nicht pathologisch waren. Bei Personen mit reaktiv aktiviertem Gerinnungssystem war ebenfalls eine erhöhte Thrombinbildung nachweisbar, zudem war die aPTT verkürzt. Dagegen zeigten Personen mit Antiphospholipidsyndrom und Personen mit heterozygoter/homozygoter FV-Leiden-Mutation eine leicht gesteigerte Thrombinbildung, ferner waren die anderen plasmatischen Tests (PT, aPTT, TZ), außer der Lupus-Antikoagulans-sensitiven aPTT, unauffällig. In dieser Arbeit wurde mit dem Thrombingenerierungstest (TGT) eine Methode etabliert und evaluiert, um die in-vitro Wirksamkeit neuer Antithrombotika auf die Blutgerinnung zu untersuchen. Die verwendeten Antithrombotika repräsentieren 3 Klassen oral applizierbarer, niedermolekularer Substanzen: 1. Thrombininhibitoren (Dabigatran und Melagatran) 2. FXa-Inhibitoren (Rivaroxaban und Apixaban) 3. Duale Thrombin/FXa-Inhibitoren (BR4965 und BR4966) Die Ergebnisse der vorliegenden Arbeit zeigen, dass Antithrombotika je nach Wirkmechanismus (FXa-Hemmung, Thrombinhemmung oder duale Thrombin/FXa-Hemmung) unterschiedliche Effekte auf die TGT-Parameter ETP (endogenes Thrombinpotential) und PEAK (größte Thrombinbildungsgeschwindigkeit) haben. Während der PEAK gut geeignet war, die antihämostatische Wirkung von selektiven FXa-Inhibitoren abzubilden, wurde das ETP durch die FXa-Inhibitoren nicht so stark beeinflusst, insbesondere in plättchenarmen Plasma (PPP). Im Gegensatz dazu hatten die selektiven Thrombininhibitoren eine gute dosisabhängige Wirkung auf das ETP, jedoch keine auf den PEAK. Mehr noch wurde für Inhibitoren mit thrombinhemmender Komponente beobachtet, dass sie den PEAK der Thrombinbildung erhöhen statt reduzieren, wenn sie in niedrigen Konzentrationen zugegeben wurden. Dieses Phänomen war umso stärker ausgeprägt, je höher die Thrombinselektivität der Substanz war. Erwartungsgemäß zeigten die beiden dualen Thrombin/FXa-Inhibitoren sowohl Eigenschaften von FXa-Inhibitoren, als auch von selektiven Thrombininhibitoren, wobei die Substanz BR4965 in ihrer Wirkung eher den FXa-Inhibitoren ähnelte und BR4966 eher den selektiven Thrombininhibitoren. In PPP und PRP (plättchenreichem Plasma) von Personen mit aktiviertem Gerinnungssystem (heterozygote/homozygote FV-Leiden Mutation, heterozygote Prothrombin-Mutation oder reaktiv aktiviertes Gerinnungssystem) zeigten die Antithrombotika ähnliche Effekte auf die Thrombinbildung wie bei gesunden Probanden. Lediglich in PRP von Patienten mit Antiphospholipidsyndrom verursachten die Inhibitoren eine stärkere Hemmung der Thrombinbildung, insbesondere die FXa-Hemmer. Der Einfluss des FXa-Inhibitors Rivaroxaban auf die PT erwies sich als dosisabhängig und korreliert eng mit dem Plasmaspiegel, so dass mit diesem Globaltest ein einfacher Monitoring-Test zur Verfügung steht. Es ist aber zu beachten, dass die PT in Sekunden abgelesen werden muss, denn nur für eine Ablesung in Sekunden, aber nicht in % (= Quick-Wert) ergab sich eine enge Korrelation mit den Plasmaspiegeln. Für das Monitoring von selektiven Thrombininhibitoren wie Dabigatran war die aPTT besser geeignet. Die Heparin-induzierte Thrombozytopenie Typ II (HIT Typ II) ist eine schwerwiegende Komplikation der Heparin-Therapie. Daher wurde untersucht, ob die neu entwickelten Antithrombotika auch das Risiko für die Enstehung einer HIT Typ II bergen. Hierzu wurde auf Basis der Thrombinbildung ein Testsystem entwickelt, in dem gezeigt wurde, dass Plättchenfaktor 4 (PF4) die gerinnungshemmende Aktivität von Heparinen, aber nicht die der neuen Antithrombotika neutralisiert. Hieraus ist zu schließen, dass PF4 an Heparine binden kann, aber nicht an die neuen Antithrombotika. Folglich sollte das Risiko einer HIT Typ II unter den neuen Antithrombotika gering sein, da hierfür zunächst Antikörper an den Komplex aus PF4 und Heparin (bzw. PF4/Antithrombotikum) binden müssen. Abschließend wurde der Einfluss der neuen Inhibitoren auf die Ausbildung der Thrombozyten- Leukozyten-Aggregate untersucht, da bei akuten thromboembolischen Ereignissen (z.B. Herzinfarkt) erhöhte Werte von Thrombozyten-Leukozyten-Aggregaten nachgewiesen wurden. Alle untersuchten Substanzen hatten eine inihibitorische Wirkung auf die Ausbildung der Thrombozyten-Leukozyten-Aggregate, wobei der hemmende Effekt umso stärker ausgeprägt war, je höher die Thrombinselektivität des Inhibitors war. In dieser Arbeit wurde mit dem Thrombingenerierungstest (TGT) eine Methode etabliert und evaluiert, um die in-vitro Wirksamkeit neuer Antithrombotika auf die Blutgerinnung zu untersuchen. Die verwendeten Antithrombotika repräsentieren 3 Klassen oral applizierbarer, niedermolekularer Substanzen: 1. Thrombininhibitoren (Dabigatran und Melagatran) 2. FXa-Inhibitoren (Rivaroxaban und Apixaban) 3. Duale Thrombin/FXa-Inhibitoren (BR4965 und BR4966) Die Ergebnisse der vorliegenden Arbeit zeigen, dass Antithrombotika je nach Wirkmechanismus (FXa-Hemmung, Thrombinhemmung oder duale Thrombin/FXa-Hemmung) unterschiedliche Effekte auf die TGT-Parameter ETP (endogenes Thrombinpotential) und PEAK (größte Thrombinbildungsgeschwindigkeit) haben. Während der PEAK gut geeignet war, die antihämostatische Wirkung von selektiven FXa-Inhibitoren abzubilden, wurde das ETP durch die FXa-Inhibitoren nicht so stark beeinflusst, insbesondere in plättchenarmen Plasma (PPP). Im Gegensatz dazu hatten die selektiven Thrombininhibitoren eine gute dosisabhängige Wirkung auf das ETP, jedoch keine auf den PEAK. Mehr noch wurde für Inhibitoren mit thrombinhemmender Komponente beobachtet, dass sie den PEAK der Thrombinbildung erhöhen statt reduzieren, wenn sie in niedrigen Konzentrationen zugegeben wurden. Dieses Phänomen war umso stärker ausgeprägt, je höher die Thrombinselektivität der Substanz war. Erwartungsgemäß zeigten die beiden dualen Thrombin/FXa-Inhibitoren sowohl Eigenschaften von FXa-Inhibitoren, als auch von selektiven Thrombininhibitoren, wobei die Substanz BR4965 in ihrer Wirkung eher den FXa-Inhibitoren ähnelte und BR4966 eher den selektiven Thrombininhibitoren. In PPP und PRP (plättchenreichem Plasma) von Personen mit aktiviertem Gerinnungssystem (heterozygote/homozygote FV-Leiden Mutation, heterozygote Prothrombin-Mutation oder reaktiv aktiviertes Gerinnungssystem) zeigten die Antithrombotika ähnliche Effekte auf die Thrombinbildung wie bei gesunden Probanden. Lediglich in PRP von Patienten mit Antiphospholipidsyndrom verursachten die Inhibitoren eine stärkere Hemmung der Thrombinbildung, insbesondere die FXa-Hemmer. Der Einfluss des FXa-Inhibitors Rivaroxaban auf die PT erwies sich als dosisabhängig und korreliert eng mit dem Plasmaspiegel, so dass mit diesem Globaltest ein einfacher Monitoring-Test zur Verfügung steht. Es ist aber zu beachten, dass die PT in Sekunden abgelesen werden muss, denn nur für eine Ablesung in Sekunden, aber nicht in % (= Quick-Wert) ergab sich eine enge Korrelation mit den Plasmaspiegeln. Für das Monitoring von selektiven Thrombininhibitoren wie Dabigatran war die aPTT besser geeignet. Die Heparin-induzierte Thrombozytopenie Typ II (HIT Typ II) ist eine schwerwiegende Komplikation der Heparin-Therapie. Daher wurde untersucht, ob die neu entwickelten Antithrombotika auch das Risiko für die Enstehung einer HIT Typ II bergen. Hierzu wurde auf Basis der Thrombinbildung ein Testsystem entwickelt, in dem gezeigt wurde, dass Plättchenfaktor 4 (PF4) die gerinnungshemmende Aktivität von Heparinen, aber nicht die der neuen Antithrombotika neutralisiert. Hieraus ist zu schließen, dass PF4 an Heparine binden kann, aber nicht an die neuen Antithrombotika. Folglich sollte das Risiko einer HIT Typ II unter den neuen Antithrombotika gering sein, da hierfür zunächst Antikörper an den Komplex aus PF4 und Heparin (bzw. PF4/Antithrombotikum) binden müssen. Abschließend wurde der Einfluss der neuen Inhibitoren auf die Ausbildung der Thrombozyten- Leukozyten-Aggregate untersucht, da bei akuten thromboembolischen Ereignissen (z.B. Herzinfarkt) erhöhte Werte von Thrombozyten-Leukozyten-Aggregaten nachgewiesen wurden. Alle untersuchten Substanzen hatten eine inihibitorische Wirkung auf die Ausbildung der Thrombozyten-Leukozyten-Aggregate, wobei der hemmende Effekt umso stärker ausgeprägt war, je höher die Thrombinselektivität des Inhibitors war.
In the title compound, C27H20F6N2O2, the dihedral angles between the planes of the aromatic rings connected by the ether O atoms are 84.13 (8) and 75.06 (9)°. The crystal structure is stabilized by N-H...O and N-H...F hydrogen bonds. Key indicators: single-crystal X-ray study; T = 173 K; mean σ(C–C) = 0.004 Å; R factor = 0.037; wR factor = 0.088; data-to-parameter ratio = 8.2.
In the title compound, C17H12F2N2OS, the planar thiazole ring (r.m.s. deviation = 0.012 Å) makes dihedral angles of 15.08 (9) and 81.81 (6)° with the 4-fluorophenyl and 2-fluorophenyl rings, respectively. The 2-fluorophenyl ring is disordered over two orientations with site-occupancy factors of 0.810 (3) and 0.190 (3). The structure contains intermolecular C-H...O hydrogen bonds. Key indicators: single-crystal X-ray study; T = 173 K; mean σ(C–C) = 0.003 Å; disorder in main residue; R factor = 0.034; wR factor = 0.082; data-to-parameter ratio = 16.1.
The title compound, C16H14N4, features an aromatic ring with two 2,2´-dicyanopropyl residues in positions 1 and 3, which are located above and below the ring plane. The two residues differ in their conformation with respect to the aromatic ring: whereas one of the Cmethyl-C-Cmethylene-Caromatic torsion angles is gauche [68.93 (12)°], the other one is fully staggered [177.63 (9)°]. The crystal structure is stabilized by C-H...N hydrogen-bonding interactions. Key indicators: single-crystal X-ray study; T = 173 K; mean σ(C–C) = 0.002 Å; R factor = 0.037; wR factor = 0.101; data-to-parameter ratio = 15.0.
4-Chloro-N-m-tolylbenzamide
(2009)
In the title compound, C14H12ClNO, the dihedral angle between the two aromatic rings is 11.29 (15)°. The crystal packing is stabilized by N-H...O hydrogen bonds linking the molecules into chains running along the c axis. Key indicators: single-crystal X-ray study; T = 173 K; mean σ(C–C) = 0.004 Å; R factor = 0.066; wR factor = 0.178; data-to-parameter ratio = 13.7.
6-(4-Nitrophenoxy)hexanol
(2009)
The title compound, C12H17NO4, features an almost planar molecule (r.m.s. deviation for all non-H atoms = 0.070 Å). All methylene C-C bonds adopt an antiperiplanar conformation. In the crystal structure the molecules lie in planes parallel to (1\overline{1}2) and the packing is stabilized by O-H...O hydrogen bonds. Key indicators: single-crystal X-ray study; T = 173 K; mean σ(C–C) = 0.003 Å; R factor = 0.066; wR factor = 0.185; data-to-parameter ratio = 13.2.
In the title molecule, C13H16ClNO, the mean plane of the atoms in the -CONH- group forms a dihedral angle of 42.0 (4)° with the benzene ring plane. In the crystal structure, molecules are linked by intermolecular N-H...O hydrogen bonds, generating C(4) chains along [100]. Key indicators: single-crystal X-ray study; T = 173 K; mean σ(C–C) = 0.002 Å; R factor = 0.030; wR factor = 0.069; data-to-parameter ratio = 18.2.
The structure of the title compound, C14H9Cl3N2OS, is composed of discrete molecules with bond lengths and angles quite typical for thiourea compounds of this class. The plane containing the thiocarbonyl and carbonyl groups subtends dihedral angles of 48.19 (3) and 87.51 (3)° with the planes formed by the 3-chloro and 2,6-dichlorophenyl rings, respectively; the dihedral angle between the two benzene ring planes is 45.32 (3)°. An intramolecular N-H...O hydrogen bond stabilizes the molecular conformation and the molecules form intermolecular N-H...S and N-H...O hydrogen bonds, generating a sheet along the alpha axis. Key indicators: single-crystal X-ray study; T = 173 K; mean σ(C–C) = 0.002 Å; R factor = 0.037; wR factor = 0.094; data-to-parameter ratio = 25.5.
The title compound, C14H6Cl6N2OS·0.5CHCl3, crystallizes with four 1-(2,6-dichlorobenzoyl)-3- (2,3,5,6-tetrachlorophenyl)thiourea molecules and two trichloromethane molecules in the asymmetric unit. The thiourea molecules exist in the solid state in their thione forms with typical thiourea C-S and C-O bonds lengths, as well as shortened C-N bonds. The -NH-C(=S)-NH-C(=O)- plane is almost perpendicular to the benzene ring in each thiourea molecule. Intramolecular N-H...O hydrogen bonds stabilize the molecular conformation and intermolecular N-H...S hydrogen bonds stabilize the packing arrangement. Key indicators: single-crystal X-ray study; T = 173 K; mean σ(C–C) = 0.004 Å; R factor = 0.051; wR factor = 0.147; data-to-parameter ratio = 23.2.
The title molecule, C16H15ClN2OS, exists in the solid state in its thione form with typical thiourea C-S and C-O bonds lengths, as well as shortened C-N bonds. An intramolecular N-H...O hydrogen bond stabilizes the molecular conformation and intermolecular N-H...S hydrogen bonds link the molecules into centrosymmetric dimers. The dihedral angle between the aromatic rings is 50.18 (5)°. Key indicators: single-crystal X-ray study; T = 173 K; mean σ(C–C) = 0.002 Å; R factor = 0.032; wR factor = 0.085; data-to-parameter ratio = 15.3.
The asymmetric unit of the title compound, C14H8Cl4N2OS·0.5H2O, contains two independent molecules with different conformations with respect to the aromatic ring planes, and one water molecule. The bond lengths and angles are typical of thiourea compounds of this class. The molecule exists in the solid state in its thione form with typical thiourea C-S and C-O bonds lengths, as well as shortened C-N bonds. The dihedral angles between the two aromatic planes are 66.93 (8) and 60.44 (9)° in the two independent molecules. An intramolecular N-H...O hydrogen bond stabilizes the molecular conformation and the crystal packing is characterized by N-H...O, O-H...S and O-H...Cl hydrogen bonds. Key indicators: single-crystal X-ray study; T = 173 K; mean σ(C–C) = 0.004 Å; R factor = 0.045; wR factor = 0.125; data-to-parameter ratio = 16.8.
The crystal structure of the title compound, C14H8Cl4N2OS, is composed of discrete molecules with bond lengths and angles quite typical for thiourea compounds of this class. The plane containing the central SONNCC atom set subtends a dihedral angle of 31.47 (3)° with the benzene ring. An intramolecular N-H...O hydrogen bond stabilizes the molecular conformation and the molecules form centrosymmetric dimers via intermolecular N-H...S hydrogen bonds. Key indicators: single-crystal X-ray study; T = 173 K; mean σ(C–C) = 0.002 Å; R factor = 0.032; wR factor = 0.087; data-to-parameter ratio = 17.9.
The two aromatic rings in the title compound, C15H12Cl2N2O2S, enclose a dihedral angle of 37.49 (6)°. The molecule exists in the solid state in its thione form with typical thiourea C-S and C-O bonds lengths, as well as shortened C-N bonds. An intramolecular N-H...O hydrogen bond stabilizes the molecular conformation. In the crystal, molecules are connected by N-H...O and N-H...S hydrogen bonds, forming chains running along the alpha axis. Key indicators: single-crystal X-ray study; T = 173 K; mean σ (C–C) = 0.002 Å; disorder in main residue; R factor = 0.035; wR factor = 0.087; data-to-parameter ratio = 18.9.
The title compound, Cs2Mg(H2P2O7)2·2H2O, is isostructural with the related known isoformular phosphates. The crystal framework consists of corner-sharing MgO6 and H2P2O7 polyhedra, leading to tunnels parallel to the b-axis direction in which Cs+ ions are located. The H2P2O7 unit shows a bent eclipsed conformation. The Mg2+ ion lies on an inversion center. The water molecules form hydrogen bonds to O atoms of two different dihydrogenphosphate ions, which are further hydrogen bonded to symmetry-equivalent dihydrogenphosphate ions. Key indicators: single-crystal X-ray study; T = 173 K; mean σ(P–O) = 0.006 Å; R factor = 0.048; wR factor = 0.125; data-to-parameter ratio = 12.3.
The crystal structure of the title compound, C15H17BrN2O4S, is stabilized by intermolecular N-H...O hydrogen bonds which link the molecules into centrosymmetric dimers. The dihedral angle subtended by the 4-bromophenyl group with the mean plane passing through the hydantoin unit is 83.29 (5)°. The cyclohexyl group adopts an ideal chair conformation with the methyl group in an equatorial position. Key indicators: single-crystal X-ray study; T = 173 K; mean σ(C–C) = 0.003 Å; R factor = 0.030; wR factor = 0.070; data-to-parameter ratio = 16.8.
The five-membered ring of the title compound, C10H14NO, is almost planar [mean deviation from best plane = 0.006 (1) Å]. The N-O bond is in the plane of the five-membered ring. The molecule is positioned about a pseudo-mirror plane at y = 0.375. In the crystal, molecules are connected by intermolecular C-H...O contacts into layers parallel to (010). Key indicators: single-crystal X-ray study; T = 167 K; mean σ(C–C) = 0.002 Å; R factor = 0.062; wR factor = 0.157; data-to-parameter ratio = 27.3.
In the title compound, C15H17ClN2O4S, the atoms in the hydantoin ring are coplanar (r.m.s. deviation = 0.006 Å). The crystal structure is stabilized by intermolecular N-H...O hydrogen bonds which link the molecules into centrosymmetric dimers. The dihedral angle subtended by the 4-chlorophenyl group with the plane passing through the hydantoin unit is 82.98 (4)°. The cyclohexyl ring adopts an ideal chair conformation. Key indicators: single-crystal X-ray study; T = 173 K; mean σ(C–C) = 0.002 Å; R factor = 0.030; wR factor = 0.081; data-to-parameter ratio = 15.0.
In the title Grignard reagent, [MgBr(C12H9)(C5H10O)2], the Mg centre adopts a distorted tetrahedral MgCO2Br arrangement. The dihedral angle between the two aromatic rings of the biphenyl residue is 44.00 (14)°. Each molecule incorporates one R- and one S-configured 2-methyltetrahydrofuran molecule. Key indicators: single-crystal X-ray study; T = 173 K; mean σ(C–C) = 0.007 Å; R factor = 0.045; wR factor = 0.108; data-to-parameter ratio = 17.4.
The title compound, C17H18N2O6, crystallizes with two molecules in the asymmetric unit. In both molecules, one of the C-C bonds of the pentamethylene chain connecting the two aromatic rings is in a trans conformation and another displays a gauche conformation. The aromatic rings within each molecule are nearly coplanar [dihedral angles = 3.36 (9) and 4.50 (9)°] and the nitro groups are twisted slightly out of the planes of their attached rings [dihedral angles = 8.16 (3)/6.6 (2) and 4.9 (4)/3.8 (3)°]. Key indicators: single-crystal X-ray study; T = 173 K; mean σ(C–C) = 0.003 Å; R factor = 0.040; wR factor = 0.101; data-to-parameter ratio = 13.5.
In the title compound, C16H16BrNO4, the dihedral between the planes of the aromatic rings is 7.74 (18)°. The amide group is tilted with respect to the bromo- and methoxy-substituted aromatic rings by 36.3 (8) and 35.2 (8)°, respectively. The meta-methoxy groups are essentially in-plane with the aromatic ring [dihedral angles CH3-O-C-C = -4.6 (4) and -2.5 (4)°]. The para-methoxy group is markedly displaced from the ring plane [dihedral angle CH3-O-C-C = -72.5 (4)°]. The crystal packing is stabilized by N-H...O hydrogen bonds linking the molecules into chains running along the b axis. Key indicators: single-crystal X-ray study; T = 173 K; mean σ(C–C) = 0.004 Å; R factor = 0.033; wR factor = 0.076; data-to-parameter ratio = 14.6.
Adamantane-1-thioamide
(2009)
The title compound, C11H17NS, is an important intermediate for the synthesis of biologically active adamantlythiazolo-oxadiazoles. The adamantyl residue is disordered about a twofold rotation axis over two sites with site-occupation factors of 0.817 (3) and 0.183 (3). The crystal structure is stabilized by intermolecular N-H...S hydrogen-bonding interactions. Key indicators: single-crystal X-ray study; T = 173 K; mean &963;(C–C) = 0.002 Å; disorder in main residue; R factor = 0.038; wR factor = 0.103; data-to-parameter ratio = 12.3.
The title compound, C21H16N2O2, was derived from 1-(2-hydroxyphenyl)-3-(-methoxyphenyl)propane-1,3-dione. The molecular structure of the title compound is stabilized by an intramolecular O-H...N hydrogen bond. The dihedral angle between the hydroxyphenyl ring involved in this intramolecular hydrogen bond and the pyrazole ring is significantly smaller [10.07 (6)°] than the dihedral angle between the pyrazole and the other hydroxyphenyl ring [36.64 (5)°]. The benzene ring makes a dihedral angle of 54.95 (3)° with the pyrazole ring. The crystal packing is stabilized by O-H...O and O-H...N hydrogen bonds. Key indicators: single-crystal X-ray study; T = 173 K; mean σ(C–C) = 0.002 Å; R factor = 0.039; wR factor = 0.101; data-to-parameter ratio = 16.2.
The title compound, C22H18N2O2, was derived from 1-(2-hydroxyphenyl)-3-(4-methoxyphenyl)propane-1,3-dione. The central pyrazole ring forms dihedral angles of 16.83 (5), 48.97 (4) and 51.68 (4)°, respectively, with the methoxyphenyl, phenyl and hydroxyphenyl rings. The crystal packing is stabilized by O-H...N hydrogen bonding. Key indicators: single-crystal X-ray study; T = 173 K; mean σ(C–C) = 0.002 Å; R factor = 0.037; wR factor = 0.096; data-to-parameter ratio = 17.0.
The title compound, C25H22O5, was obtained by a dehydrogenative carbonylation reaction. It crystallizes with one half-molecule in the asymmetric unit. The molecules have crystallographic C2 symmetry and the two atoms of the carbonyl group are located on the rotation axis. The methoxy groups are coplanar with the benzene ring to which they are attached [C-C-O-C = 1.0 (6)°]. The two furan rings are inclined at 17.3 (3)° with respect to each other and the dihedral angle between the furan ring and the benzene ring is 75.83 (12)°. The crystal structure is stabilized by C-H...O hydrogen bonds. Key indicators: single-crystal X-ray study; T = 183 K; mean ( σ(C–C) = 0.006 Å; R factor = 0.081; wR factor = 0.195; data-to-parameter ratio = 13.4.
The title molecule, C14H9ClN2OS, exists in the solid state in its amide form with a typical C=O bond length, as well as shortened C-N bonds. The plane containing the HNCO atoms subtends dihedral angles of 12.3 (4) and 8.1 (3)° with the planes of the phenyl ring and benzothiazole group, respectively, whereas the dihedral angle between the planes of the phenyl ring and the benzothiazole group is 5.96 (6)°. In the crystal, molecules form intermolecular N-H...N hydrogen bonds, generating independent scissor-like R22(8) dimers. Key indicators: single-crystal X-ray study; T = 173 K; mean σ(C–C) = 0.002 Å; R factor = 0.028; wR factor = 0.079; data-to-parameter ratio = 13.3.
In the molecule of the title compound, C14H16ClN3O, the benzene and pyrazole rings are oriented at a dihedral angle of 3.50 (3)°. In the crystal structure, intermolecular N-H...O hydrogen bonds link the molecules into chains. A [pi]-[pi] contact between the benzene and pyrazole rings [centroid-centroid distance = 3.820 (3) Å] may further stabilize the structure. Key indicators: single-crystal X-ray study; T = 173 K; mean σ(C–C) = 0.002 Å; R factor = 0.031; wR factor = 0.086; data-to-parameter ratio = 14.1.
2-Chloro-5-nitroaniline
(2009)
The molecule of the title compound, C6H5ClN2O2, is close to being planar (rms deviation = 0.032 Å for all non-H atoms), with a maximum deviation of -0.107 (3) Å for an O atom. In the crystal structure, intermolecular N-H...O and N-H...N interactions link the molecules into a three-dimensional network. Key indicators: single-crystal X-ray study; T = 173 K; mean σ(C–C) = 0.002 A°; R factor = 0.023; wR factor = 0.061; data-to-parameter ratio = 11.8.
4-(4-Nitrophenoxy)biphenyl
(2009)
The two phenyl rings of the biphenyl unit of the title compound, C18H13NO3, are almost coplanar [dihedral angle 6.70 (9)°]. The nitrophenyl ring, on the other hand, is significantly twisted out of the plane of the these two rings, making dihedral angles of 68.83 (4)° with the middle ring and 62.86 (4)° with the end ring. The nitro group is twisted by 12.1 (2)° out of the plane of the phenyl ring to which it is attached. Key indicators: single-crystal X-ray study; T = 173 K; mean σ(C–C) = 0.002 A° ; R factor = 0.040; wR factor = 0.118; data-to-parameter ratio = 12.8.
The six-membered ring of the title compound, C11H16NO, has a distorted envelope conformation. The piperidine N atom deviates by 0.128 (1) Å from the plane through its three neighbouring atoms. In the crystal structure, molecules are connected by intermolecular Cethynyl-H...O contacts to form chains extending in the [10\overline{1}] direction. Key indicators: single-crystal X-ray study; T = 167 K; mean σ(C–C) = 0.001 Å ; R factor = 0.040; wR factor = 0.112; data-to-parameter ratio = 27.3.
Molecules of the title compound, C40H42BrNO6, are located on a crystallographic twofold rotation axis. As a result, the nitro group and bromine residue are mutually disordered with equal occupancies. The propoxy-substituted aromatic rings are close to parallel to each other [dihedral angle = 21.24 (1)°], whereas the propenoxy-substituted rings enclose a dihedral angle of 70.44 (1)°. The dihedral angles between the methylene C atoms and the aromatic rings shows that the propenoxy substituted rings are bent away from the calixarene cavity [dihedral angle between the planes = 35.22 (8)°], whereas the propoxy-substituted rings are almost perpendicular [79.38 (10)°] to the plane of the methylene C atoms. Key indicators: single-crystal X-ray study; T = 173 K; mean σ(C–C) = 0.006 A° ; disorder in main residue; R factor = 0.065; wR factor = 0.130; data-to-parameter ratio = 11.8.
The asymmetric unit of the title compound, [K(C3H3N2)(C12H24O6)], is composed of a potassium cation bonded to the six O atoms of a crown ether molecule and the two N atoms of a pyrazolate anion. The K...O distances range from 2.8416 (8) to 3.0025 (8) Å, and the two K...N distances are 2.7441 (11) and 2.7654 (11) Å. The K cation is displaced by 0.8437 (4) Å from the best plane through the six O atoms. The latter plane is almost perpendicular to the plane of the pyrazolate ring [dihedral angle 83.93 (3)°]. Key indicators: single-crystal X-ray study; T = 173 K; mean σ(C–C) = 0.002 A°; R factor = 0.026; wR factor = 0.066; data-to-parameter ratio = 16.5.
The title compound, C14H9Cl3N2OS, has bond lengths and angles which are quite typical for thiourea compounds of this class. The molecule exists in the solid state in its thione form with typical thiourea C=S and C=O bond lengths, as well as shortened C-N bonds. An intramolecular N-H...O hydrogen bond stabilizes the molecular conformation. Intermolecular N-H...S hydrogen bonds link the molecules to form centrosymmetric dimers. Key indicators: single-crystal X-ray study; T = 173 K; mean σ(C–C) = 0.002 A° ; R factor = 0.029; wR factor = 0.078; data-to-parameter ratio = 17.2.
In the title compound, C30H34N2O6, the complete molecule is generated by a crystallographic 2/m symmetry operation. The 1-oxyl-3-pyrroline-3-carboxylate group lies on a mirror plane. The dihedral angle between the ring planes of the biphenyl fragment is constrained by symmetry to be zero, resulting in rather short intramolecular H...H contact distances of 2.02 Å. In the crystal, molecules are connected along the a-axis direction by very weak intermolecular methyl-phenyl C-H...[pi] interactions. The C-H bond is not directed to the center of the benzene ring, but mainly to one C atom [C-H...C(x - 1, y, z): H...C = 2.91 Å and C-H...C = 143°]. Key indicators: single-crystal X-ray study; T = 169 K; mean σC–C) = 0.002 Å ; R factor = 0.049; wR factor = 0.126; data-to-parameter ratio = 19.8.
Die vorliegende Arbeit befasst sich mit der Entwicklung von neuen enantioselektiven und diastereoselektiven Brønsted-Säure katalysierten Reaktionen. Das Aktivierungsprinzip entspricht dabei einer klassischen Säure-Base-Reaktion, in der eine Brønsted-Säure einen Elektronenpaar-Donor protoniert, woraus die Bildung eines Ionenpaares resultiert. Erweitert man dieses Konzept durch den Einsatz einer chiralen Protonenquelle und verwendet als Base ein prochirales Substrat, wie ein Imin, so entsteht durch dessen Protonierung ein chirales Ionenpaar, wodurch das Substrat einerseits aktiviert wird und anderseits asymmetrische Induktion über das chirale Anion erfährt. Greift in dem darauf folgenden Schritt ein Nucleophil selektiv über eine Seite des positiv geladenen Elektrophils an, so bildet sich enantioselektiv ein neues Stereozentrum. Die Natur nutzt dieses Prinzip zum Aufbau von optisch reinen α-Aminosäuren. So katalysiert die Glutamatdehydrogenase (GDH) die Darstellung von Glutaminsäure durch Protonierung des entsprechenden α-Iminoglutarats, wodurch der nachfolgende Hydrid-Angriff mittels Nicotinamidadenindinukleotid (NADH) selektiv die (L)-Aminosäure liefert. Dieses Konzept konnte während der eigenen Diplomarbeit auf die enantioselektive Brønsted-Säure katalysierte Transferhydrierung von Ketiminen übertragen werden. Dabei simuliert eine chirale Protonenquelle 1 das Enzym (GDH) und das Reduktionsmittel NADH wird durch ein synthetisches Analogon, das Hantzsch Dihydropyridin 8a ersetzt ... Die vorliegende Arbeit ist kumulativ verfasst. Der größte Teil der hier vorgestellten Ergebnisse ist bereits veröffentlicht oder zur Publikation eingereicht. Die experimentellen Daten sind Bestandteil der in Kapitel 10 aufgeführten Publikationen und werden nicht gesondert diskutiert. Folgende Teile dieser Arbeit wurden bereits veröffentlicht: Highly Enantioselective Organocatalytic Carbonyl-Ene Reaction with strongly Acid, Chiral Brønsted Acids as Efficient Catalysts Rueping M., Theissmann T., Kuenkel A., Koenigs R.M., Angewandte Chemie International Edition 2008, 47, 6798, Angewandte Chemie 2008, 120, 6903. Asymmetric counterion pair catalysis: An enantioselective Brønsted acid-catalyzed protonation Rueping M., Theissmann T., Raja S., Bats J.W., Advanced Synthesis & Catalysis 2008, 350, 1001. An enantioselective chiral brønsted acid catalyzed imino-azaenamine reaction Rueping M., Sugiono E., Theissmann T., Kuenkel A., Köckritz A., Pews-Davtyan A., Nemati N., Beller M., Organic Letters 2007, 9, 1065. Remarkably low catalyst loading in Brønsted acid catalyzed transfer hydrogenations: Enantioselective reduction of benzoxazines, benzothiazines, and benzoxazinones Rueping M., Antonchick A.P., Theissmann T., Angewandte Chemie International Edition 2006, 45, 6751, Angewandte Chemie 2006, 118, 6903. A highly enantioselective brønsted acid catalyzed cascade reaction: Organocatalytic transfer hydrogenation of quinolines and their application in the synthesis of alkaloids Rueping M., Antonchick A.P., Theissmann T., Angewandte Chemie International Edition 2006, 45, 3683, Angewandte Chemie 2006, 118, 3765. Metal-free Brønsted acid catalyzed transfer hydrogenation - New organocatalytic reduction of quinolines Rueping M., Theissmann, T., Atonchick A.P., Synlett 2006, 1071. The twinned crystal structure of diiodobis(triphenylphosphine) palladium(II) dichloromethane disolvate at 173 K Theissmann T., Bolte M., Acta Crystallographica Section E, 2006, E62, 1056. Folgende Manuskripte wurden zur Veröffentlichung eingereicht: First Enantioselective Chiral Brønsted Acid Catalyzed Synthesis of 4´-Substituted Tetrahydroquinolines Rueping M., Theissmann T., Stoeckel M., Atonchick A.P. Asymmetric Organocatalytic Reductions in the Enantioselective Synthesis of Fluoroquinolones, Flumiquine and Levofloxacin Rueping M, Stoeckel M., Theissmann T., Haack K. Synthesis and Structural Investigations of H8-BINOL-derived N-triflylphosphoramides Rueping M., Nachtsheim B.J., Koenigs R., Ieawsuwan W., Theissmann T. Buchbeitrag: Metal-free Brønsted Acid Catalyzed Transfer-Hydrogenation: Enantioselective Synthesis of Tetrahydroquinolines Rueping M., Theissmann T., Atonchick A.P., Catalysts for Fine Chemical Industry, Vol. 5, 2006
The title compound, C14H20O3, is a synthetic analogue with a long aliphatic side chain of the important food additive and flavoring agent, vanillin. There are two independent molecules in the asymmetric unit, each having an essentially planar conformation (r.m.s. deviations of 0.023 and 0.051Å for all non-H atoms of the two molecules in the asymmetric unit). Key indicators: single-crystal X-ray study; T = 173 K; mean σ(C–C) = 0.002 A°; R factor = 0.049; wR factor = 0.144; data-to-parameter ratio = 15.9.
The title compound, C20H22O2, crystallizes with two independent molecules in the asymmetric unit. In each molecule, all the non-H atoms lie in a common plane (r.m.s. deviations of 0.098 and 0.079 Å). There is a [pi]-[pi] stacking interaction in the crystal structure. The central aromatic rings of the two molecules, which are stacked head-to-tail one above the other, are separated by centroid-to-centroid distances of 3.872 (13) and 3.999 (10) Å. Key indicators: single-crystal X-ray study; T = 173 K; mean σ(C–C) = 0.003 A° ; R factor = 0.044; wR factor = 0.101; data-to-parameter ratio = 14.6.
In the title compound, C11H14O4, an intermediate for the synthesis of a new kind of estrogen receptor modulator, all non-H atoms lie on a common plane (r.m.s. deviation = 0.0472 Å). All C-C bonds in the side chain are in a trans conformation, and the hydroxyl group is also trans to the methylene chain. In the crystal structure, molecules form centrosymmetric dimers showing a head-to-head arrangement which is stabilized by O-H...O hydrogen bonds. A weak C-H...O contact is also present.
9,9-Dimethyl-9-silafluorene
(2009)
The title compound, C14H14Si, crystallizes with two almost identical molecules (r.m.s. deviation = 0.080 Å for all non-H atoms) in the asymmetric unit. All atoms of the silafluorene moiety lie in a common plane (r.m.s. deviations = 0.049 and 0.035 Å for the two molecules in the asymmetric unit). The Si-Cmethyl bonds are significantly shorter [1.865 (4)-1.868 (4) Å] than the Si-Caromatic bonds [1.882 (3)-1.892 (3) Å]. Owing to strain in the five-membered ring, the endocyclic C-Si-C angles are reduced to 91.05 (14) and 91.21 (14)°. Key indicators: single-crystal X-ray study; T = 173 K; mean σ(C–C) = 0.005 A°; R factor = 0.061; wR factor = 0.157; data-to-parameter ratio = 16.3.
The complete molecule of the title compound, C18H24N2O2, is generated by a crystallographic inversion centre. The torsion angles in the hexamethylene chain are consistent with an antiperiplanar conformation, whereas the conformation of the O—CH2—CH2—CH2 unit is gauche. The three-dimensional crystal packing is stabilized by N—H⋯O and N—H⋯N hydrogen bonding.
The Mg centre in the title compound, [MgBr2(C2H7N)3], is pentacoordinated in a trigonal-bipyramidal mode with the two Br atoms in axial positions and the N atoms of the dimethylamine ligands in equatorial positions. The MgII centre is located on a crystallographic twofold rotation axis. The crystal structure is stabilized by N—H⋯Br hydrogen bonds. The N atom and H atoms of one dimethylamine ligand are disordered over two equally occupied positions.
Modelling protein flexibility and plasticity is computationally challenging but important for understanding the function of biological systems. Furthermore, it has great implications for the prediction of (macro) molecular complex formation. Recently, coarse-grained normal mode approaches have emerged as efficient alternatives for investigating large-scale conformational changes for which more accurate methods like MD simulation are limited due to their computational burden. We have developed a Normal Mode based Simulation (NMSim) approach for efficient conformation generation of macromolecules. Combinations of low energy normal modes are used to guide a simulation pathway, whereas an efficient constraints correction approach is applied to generate stereochemically allowed conformations. Non-covalent bonds like hydrogen bonds and hydrophobic tethers and phi-psi favourable regions are also modelled as constraints. Conformations from our approach were compared with a 10 ns MD trajectory of lysozyme. A 2-D RMSD plot shows a good overlap of conformational space, and rms fluctuations of residues show a correlation coefficient of 0.78 between the two sets of conformations. Furthermore, a comparison of NMSim simulations starting from apo structures of different proteins show that ligand-bound conformations can be sampled for those cases where conformational changes are mainly correlated, e.g., domain-like motion in adenylate kinase. Efforts are currently being made to also model localized but functionally important motions for protein binding pockets and protein-protein interfaces using relevant normal mode selection criteria and implicit rotamer basin creation.
A new method to bridge the gap between ligand and receptor-based methods in virtual screening (VS) is presented. We introduce a structure-derived virtual ligand (VL) model as an extension to a previously published pseudo-ligand technique [1]: LIQUID [2] fuzzy pharmacophore virtual screening is combined with grid-based protein binding site predictions of PocketPicker [3]. This approach might help reduce bias introduced by manual selection of binding site residues and introduces pocket shape information to the VL. It allows for a combination of several protein structure models into a single "fuzzy" VL representation, which can be used to scan screening compound collections for ligand structures with a similar potential pharmacophore. PocketPicker employs an elaborate grid-based scanning procedure to determine buried cavities and depressions on the protein's surface. Potential binding sites are represented by clusters of grid probes characterizing the shape and accessibility of a cavity. A rule-based system is then applied to project reverse pharmacophore types onto the grid probes of a selected pocket. The pocket pharmacophore types are assigned depending on the properties and geometry of the protein residues surrounding the pocket with regard to their relative position towards the grid probes. LIQUID is used to cluster representative pocket probes by their pharmacophore types describing a fuzzy VL model. The VL is encoded in a correlation vector, which can then be compared to a database of pre-calculated ligand models. A retrospective screening using the fuzzy VL and several protein structures was evaluated by ten fold cross-validation with ROC-AUC and BEDROC metrics, obtaining a significant enrichment of actives. Future work will be devoted to prospective screening using a novel protein target of Helicobacter pylori and compounds from commercial providers.
Protein kinases are targets for drug development. Dysregulation of kinase activity leads to various diseases, e.g. cancer, inflammation, diabetes. Human polo-like kinase 1 (Plk1), a serine/threonine kinase, is a cancer-relevant gene and a potential drug target which attracts increasing attention in the field of cancer therapy. Plk1 is a key player in mitosis and modulates entry into mitosis and the spindle checkpoint at the meta-/anaphase transition. Plk1 overexpression is observed in various human tumors, and it is a negative prognostic factor for cancer patients. The same catalytical mechanism and the same co-substrate (ATP) lead to the problem of inhibitor selectivity. A strategy to solve this problem is represented by targeting the inactive conformation of kinases. Kinases undergo conformational changes between active and inactive conformation and thus an additional hydrophobic pocket is created in the inactive conformation where the surrounding amino acids are less conserved. A "homology model" of the inactive conformation of Plk1 was constructed, as the crystal structure in its inactive conformation is unknown. A crystal structure of Aurora A kinase served as template structure. With this homology model a receptor-based pharmacophore search was performed using SYBYL7.3 software. The raw hits were filtered using physico-chemical properties. The resulting hits were docked using Gold3.2 software, and 13 candidates for biological testing were manually selected. Three compounds of the 13 tested exhibit anti-proliferative effects in HeLa cancer cells. The most potent inhibitor, SBE13, was further tested in various other cancer cell lines of different origins and displayed EC50 values between 12 microM and 39 microM. Cancer cells incubated with SBE13 showed induction of apoptosis, detected by PARP (Poly-Adenosyl-Ribose-Polymerase) cleavage, caspase 9 activation and DAPI staining of apoptotic nuclei.
For a virtual screening study, we introduce a combination of machine learning techniques, employing a graph kernel, Gaussian process regression and clustered cross-validation. The aim was to find ligands of peroxisome-proliferator activated receptor gamma (PPAR-y). The receptors in the PPAR family belong to the steroid-thyroid-retinoid superfamily of nuclear receptors and act as transcription factors. They play a role in the regulation of lipid and glucose metabolism in vertebrates and are linked to various human processes and diseases. For this study, we used a dataset of 176 PPAR-y agonists published by Ruecker et al. ...
Two methods for the fast, fragment-based combinatorial molecule assembly were developed. The software COLIBREE® (Combinatorial Library Breeding) generates candidate structures from scratch, based on stochastic optimization [1]. Result structures of a COLIBREE design run are based on a fixed scaffold and variable linkers and side-chains. Linkers representing virtual chemical reactions and side-chain building blocks obtained from pseudo-retrosynthetic dissection of large compound databases are exchanged during optimization. The process of molecule design employs a discrete version of Particle Swarm Optimization (PSO) [2]. Assembled compounds are scored according to their similarity to known reference ligands. Distance to reference molecules is computed in the space of the topological pharmacophore descriptor CATS [3]. In a case study, the approach was applied to the de novo design of potential peroxisome proliferator-activated receptor (PPAR gamma) selective agonists. In a second approach, we developed the formal grammar Reaction-MQL [4] for the in silico representation and application of chemical reactions. Chemical transformation schemes are defined by functional groups participating in known organic reactions. The substructures are specified by the linear Molecular Query Language (MQL) [5]. The developed software package contains a parser for Reaction-MQL-expressions and enables users to design, test and virtually apply chemical reactions. The program has already been used to create combinatorial libraries for virtual screening studies. It was also applied in fragmentation studies with different sets of retrosynthetic reactions and various compound libraries.